Search - tctmd.com

Displaying 61 - 80 of 128

Sort: Relevancy | Date

News Daily News

Antiplatelets Protective Post-TAVR in A-fib Patients: PARTNER II Data

Caitlin E. Cox

August 21, 2019

News Daily News

Expert Consensus Gives Initial Guidance on Post-TAVR Conduction Disturbances

Yael L. Maxwell

August 20, 2019

News Daily News

FDA Expands TAVR Indication to Low-Risk Patients

Michael O'Riordan

August 16, 2019

News Daily News

Evolut Valves: Initial Positioning Can Be Optimized for Future Coronary Access

Michael O'Riordan

July 10, 2019

News Daily News

Platelet Function and Genetic Testing to Guide P2Y12 Inhibitor Meds in PCI: Updated Consensus

Caitlin E. Cox

June 13, 2019

News Daily News

EXCEL Insights: CABG Outcomes for Left Main CAD Have Improved Substantially

Michael O'Riordan

April 22, 2019

News Daily News

Latest Observational Data Support TAVR Durability Through 7 Years

Caitlin E. Cox

April 12, 2019

News Daily News

Survival Better With Early AVR for Severe Asymptomatic Aortic Stenosis, Says Retrospective Study

L.A. McKeown

March 29, 2019

News Daily News

CMS Coverage Plan Keeps Volume Requirements for Existing TAVR Programs but Lowers Bar for New Centers

Michael O'Riordan

March 27, 2019

News Daily News

Lotus Maintains Good Safety, Efficacy at 2 Years, Though Questions Persist Over Permanent Pacing

Yael L. Maxwell

March 01, 2019

News Daily News

New Leaflet Thrombosis After TAVR Seen Out to 3 Years: OCEAN-TAVI

Shelley Wood

February 19, 2019

News Daily News

FORWARD Registry: Low Mortality Rate Seen 1 Year After TAVR With Evolut R

Todd Neale

November 20, 2018

News Daily News

TAVR Superior to Surgery at Getting High-Risk Patients Home Sooner

Michael O'Riordan

September 20, 2018

News Daily News

Aging Data: Study Highlights Delays From Time of Clinical Trial Enrollment to Publication

Yael L. Maxwell

August 15, 2018

News Daily News

Leaflet Thrombosis After TAVR Not Linked With Stroke, TIA, or Mortality Risk

Michael O'Riordan

June 20, 2018

News Daily News

Low Rate of Bailout Emergency Surgery During TAVR, but Caution Still Needed

Michael O'Riordan

January 10, 2018

News Daily News

REPRISE III in Print: Now With Comparison Between Lotus, Evolut R

Shelley Wood

January 05, 2018

News Daily News

Severe Aortic Stenosis Gets Its Own Appropriate Use Criteria

Caitlin E. Cox

October 18, 2017

News Daily News

Paravalvular Regurgitation With Sapien 3 Rare but Still Can Be Deadly

Michael O'Riordan

September 27, 2017

News Daily News

Lotus Matches Sapien in Single-Center Study, but Pacemaker Use Poses Questions

Michael O'Riordan

June 06, 2017

Advertisement

Antiplatelets Protective Post-TAVR in A-fib Patients: PARTNER II Data

Expert Consensus Gives Initial Guidance on Post-TAVR Conduction Disturbances

FDA Expands TAVR Indication to Low-Risk Patients

Evolut Valves: Initial Positioning Can Be Optimized for Future Coronary Access

Platelet Function and Genetic Testing to Guide P2Y12 Inhibitor Meds in PCI: Updated Consensus

EXCEL Insights: CABG Outcomes for Left Main CAD Have Improved Substantially

Latest Observational Data Support TAVR Durability Through 7 Years

Survival Better With Early AVR for Severe Asymptomatic Aortic Stenosis, Says Retrospective Study

CMS Coverage Plan Keeps Volume Requirements for Existing TAVR Programs but Lowers Bar for New Centers

Lotus Maintains Good Safety, Efficacy at 2 Years, Though Questions Persist Over Permanent Pacing

New Leaflet Thrombosis After TAVR Seen Out to 3 Years: OCEAN-TAVI

FORWARD Registry: Low Mortality Rate Seen 1 Year After TAVR With Evolut R

TAVR Superior to Surgery at Getting High-Risk Patients Home Sooner

Aging Data: Study Highlights Delays From Time of Clinical Trial Enrollment to Publication

Leaflet Thrombosis After TAVR Not Linked With Stroke, TIA, or Mortality Risk

Low Rate of Bailout Emergency Surgery During TAVR, but Caution Still Needed

REPRISE III in Print: Now With Comparison Between Lotus, Evolut R

Severe Aortic Stenosis Gets Its Own Appropriate Use Criteria

Paravalvular Regurgitation With Sapien 3 Rare but Still Can Be Deadly

Lotus Matches Sapien in Single-Center Study, but Pacemaker Use Poses Questions

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content